fashion -WSS

fashion

author：hotspot 2025-09-29 23:28:00 - browse：41

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

“If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Even great ERs can’t make up for American health disparities

entertainment

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

Medicare drug price negotiation’s day in court

As Maui death toll rises, number of missing remains unclear

New definition of a human embryo proposed amid rapid advances

Vertex non

Trump cancels press conference intended to dispute Georgia election interference charges

focus

fashion

entertainment

Walensky prepares to leave CDC — and Congress — behind

Congressmen charge Covid hearing ‘could have been an email’

Novavax promises a turnaround & Lilly roils the obesity market

Majority of Americans think Trump's Ga. election interference case is serious: POLL

What does generative AI mean for health care? We asked experts

Medicare drug price negotiation’s day in court

Moonlake's readout produced a cash windfall. Risks remain

A $475,000 price tag for a new cancer drug: crazy or meh?

Medicare details structure of new drug price negotiation program

Quicker fix for pulse oximeters urged during FDA public meeting

hotspot

The lessons of Aduhelm, an Alzheimer's drug that was not to be

New details revealed about Purdue's marketing of OxyContin

ARCH Venture Partners is raising $3 billion for a life sciences fund

A $475,000 price tag for a new cancer drug: crazy or meh?

Living with Hashimoto's and celiac disease, and med school, too

The boys, now 6, who are gene therapy’s ‘edge case’ problem

entertainment

Wikipedia

knowledge

leisure time